Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study

Mov Disord. 2011 Jan;26(1):153-7. doi: 10.1002/mds.23406. Epub 2010 Oct 19.

Abstract

Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD. Subjective pain threshold (using thermal stimulation, thermotest), objective pain threshold (nociceptive flexion reflex), and cerebral activity (H(2)(15)O PET) during noxious and innocuous stimulations were performed. Neither subjective nor objective pain thresholds nor pain activation profile were modified by apomorphine compared with placebo in 25 PD patients. Apomorphine has no effect on pain processing in PD. We suggest that other monoamine systems than dopaminergic system could be involved.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use
  • Apomorphine / pharmacology*
  • Apomorphine / therapeutic use
  • Cerebral Cortex / diagnostic imaging
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuralgia / diagnosis
  • Neuralgia / etiology
  • Oxygen Isotopes
  • Pain Threshold / drug effects*
  • Parkinson Disease / complications
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / pathology
  • Positron-Emission Tomography / methods

Substances

  • Antiparkinson Agents
  • Oxygen Isotopes
  • Apomorphine